Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.
Epoprostenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Single arm, open-label |
| Name | Type | Description |
|---|---|---|
| Epoprostenol | DRUG | Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit |
Inclusion Criteria: 1. Signed informed consent prior to initiation of any study-mandated procedure 2. Patients who completed participation in study AC-066A301 3. Patients who have not obtained access for commercial EFI at the time of ending participation in study AC-066A301 Exclusion Criteria: 1....
Top 13 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | selexipag, Macitentan |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
Epoprostenol is used for the treatment of pulmonary arterial hypertension, a condition characterized by high blood pressure in the arteries of the lungs. It is being developed by Johnson & Johnson for this cardiovascular indication. The drug is a small molecule and is currently in Phase 3 clinical development.
Epoprostenol works as an agonist of PTGIR, the prostacyclin receptor. By activating this receptor, it mimics the effects of natural prostacyclin, leading to vasodilation and inhibition of platelet aggregation. This mechanism helps lower pulmonary arterial pressure and is beneficial in pulmonary arterial hypertension.
Epoprostenol is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is responsible for the clinical development of this small molecule for pulmonary arterial hypertension.
Epoprostenol is in Phase 3 clinical development. A Phase 3 trial has been completed, but the drug is not yet approved. It remains an investigational therapy for pulmonary arterial hypertension.
Epoprostenol has been studied in a Phase 3 clinical trial, NCT01470144, titled "Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension." This trial enrolled 41 patients and has been completed. It was an uncontrolled study without randomization or double-blinding.